Clinical Effect Of Using A Sodium-Glucose Cotransporter 2 Inhibitor In Type 2 Diabetes Mellitus

Objective: To study the clinical efficacy of inhibition of sodium-glucose cotransporter 2 (SGLT2) in the treatment of type 2 diabetics. Methods: A total of 92 type 2 diabetics were selected. They were equally divided into two groups according to a random number table method: control group (conventional hypoglycemic treatment) and observation group (dapagliflozin). Glycated hemoglobin (HbA1c), Urine glucose/Urine creatinine level, waist circumference, weight, HDL-C, LDL-C, TC, TG, drug-related adverse events, FPG and 2 h postprandial blood glucose were analyzed and compared. Results: After treatment, the HbA1c of both groups was decreased, and the HbA1c level of the observation group was lower; the Urine glucose/Urine creatinine levels of both groups was increased, and the Urine glucose/Urine creatinine levels of the observation group was higher (P < 0.05). The waist circumference and body weight of both groups were lower, and the waist circumference and body weight of the observation group was lowest (P < 0.05). The LDL-C, TC, and TG in both groups were decreased, and the observation group was lower; HDL-C in both groups was higher, and the observation group was highest (P < 0.05). The incidence of drug-related adverse events in the control group (23.91%) was significantly higher than observation group (6.52%) (P < 0.05). Compared with the control group, the FPG of the observation group was lower (P < 0.001), and the FPG level of both groups has a tendency to decrease with time (P < 0.001). Compared with the control group, the 2 h postprandial blood glucose of the observation group was lower (P < 0.001), and the 2 h postprandial blood glucose of the two groups 2 h after a meal had a tendency to decrease with time (P < 0.001). Conclusions: SGLT2 inhibitors have a significant clinical effect on type 2 diabetes patients.